Beam Therapeutics Inc. (BEAM) vs Arcus Biosciences, Inc. (RCUS)

Beam Therapeutics Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Beam Therapeutics Inc. and Arcus Biosciences, Inc. are of similar size ($2.7B and $2.5B). Beam Therapeutics Inc. grew revenue faster over the last twelve months: 163.3% against −58.3%. Beam Therapeutics Inc. has the higher net margin (−73.9% vs −453.0%) and the lower return on invested capital (−2,676.9% vs 0.00%). Across the 17 metrics below, Beam Therapeutics Inc. leads on 15 and Arcus Biosciences, Inc. on 2.

Valuation

Metric BEAM RCUS Biotechnology median
P/E n/m n/m 10.26
P/S 18.63 22.77 9.18
P/B 2.87 6.36 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 12.20 17.49 8.98
Earnings yield (3.85%) (20.31%) (34.89%)
Free cash flow yield (14.57%) (20.51%) (24.52%)

Profitability

Metric BEAM RCUS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (267.68%) (475.00%) 0.00%
Net margin (73.89%) (453.00%) 0.00%
Free cash flow margin (271.57%) (465.00%) 0.00%
Return on equity (11.29%) (114.11%) (50.12%)
Return on assets (8.40%) (50.56%) (45.60%)
Return on invested capital (2,676.86%) 0.00% 0.00%

Growth

Metric BEAM RCUS Biotechnology median
Revenue growth (TTM) 163.27% (58.33%) 6.26%
EPS growth (last fiscal year) 82.31% (4.78%) 29.88%
Revenue growth, 5-year CAGR 466.27% 25.93% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM RCUS Biotechnology median
Debt to equity 0.11 0.28 0.00
Current ratio 13.00 3.34 4.89
Net debt to EBITDA 3.30 2.27 1.01

Dividend

Metric BEAM RCUS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BEAM RCUS Biotechnology median
Market cap 2.68b 2.51b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack